@article {1580506,
	title = {Angiotensin Converting Enzyme-Inhibitors and Incidence of Non-infectious Uveitis in a Large Healthcare Claims Database},
	journal = {Ophthalmic Epidemiol},
	year = {2021},
	month = {2021 Feb 23},
	pages = {1-6},
	abstract = {: To determine if angiotensin converting enzyme-inhibitors (ACE-I) alter the incidence of non-infectious uveitis (NIU). Patients in a large healthcare claims database who initiated ACE-I (n\&nbsp;=\&nbsp;695,557) were compared to patients who initiated angiotensin receptor blockers (ARB, n =\&nbsp;354,295). A second comparison was also made between patients who initiated ACE-I (n\&nbsp;=\&nbsp;505,958) and those who initiated beta-blockers (BB, n =\&nbsp;538,109). The primary outcome was incident NIU defined as a first diagnosis code for NIU followed by a second instance of a NIU code within 120\&nbsp;days. For the secondary outcome, a corticosteroid prescription or code for an ocular corticosteroid injection within 120\&nbsp;days of the NIU diagnosis code was used instead of the second NIU diagnosis code. Data were analyzed using Cox regression modeling with inverse probability of treatment weighting (IPTW). Sub-analyses were performed by anatomic subtype. When comparing ACE-I to ARB initiators, the hazard ratio (HR) for incident NIU was not significantly different for the primary outcome [HR\&nbsp;=\&nbsp;0.95, 95\% Confidence Interval (CI): 0.85-1.07, =\&nbsp;.41] or secondary outcome [HR\&nbsp;=\&nbsp;0.96, 95\% CI: 0.86-1.07, =\&nbsp;.44]. Similarly, in the ACE-I and BB initiators comparison, the HR for incident NIU was not significantly different comparing ACE-I and BB initiators for either outcome definition or any of the NIU anatomical subtypes. Our results suggest there is no evidence that ACE-I have a protective effect on NIU.},
	issn = {1744-5086},
	doi = {10.1080/09286586.2021.1887284},
	author = {Sobrin, Lucia and Yu, Yinxi and Li, Ashley and Kempen, John H and Hubbard, Rebecca A and VanderBeek, Brian L}
}
